SUDA continues to make progress with anagrelide. In an animal model, SUDA was able to show that an oral spray formulation had 43% higher bioavailability over a capsule form while only showing a 28% increase in exposure of the cardiostimulatory metabolite. This provides evidence that this formulation may allow for a lower dose of anagrelide, maintaining efficacy, but with reduced cardiotoxicity, a significant issue with the capsule formulation. In February, the company announced that it has contr ....
11 Mar 2021
Suda Pharmaceuticals - Half-year update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Suda Pharmaceuticals - Half-year update
Arovella Therapeutics Limited (ALA:ASX) | 0 0 6.7% | Mkt Cap: 19.5m
- Published:
11 Mar 2021 -
Author:
Maxim Jacobs -
Pages:
6
SUDA continues to make progress with anagrelide. In an animal model, SUDA was able to show that an oral spray formulation had 43% higher bioavailability over a capsule form while only showing a 28% increase in exposure of the cardiostimulatory metabolite. This provides evidence that this formulation may allow for a lower dose of anagrelide, maintaining efficacy, but with reduced cardiotoxicity, a significant issue with the capsule formulation. In February, the company announced that it has contr ....